JRJon C. Rittenberger

Jon C. Rittenberger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jon C. Rittenberger has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perceived Exertion and Physical Demand of Performing 10-Minutes of Compression-only CPR: A Randomized Simulation Study

    by Katharyn L Flickinger, Peter Prescott, Ryann DeMaio, Alexandra Weissman, David Salcido, Patrick J Coppler, Cecelia Ratay, Elizabeth Nagle, Jon Rittenberger, Fred Goss, et al.

  • Open Access

    Variability of automated external defibrillator (AED) signage across six continents: a descriptive cross-sectional study

    by Sanjana Karamcheti, Christian K. Beÿ, Blake K. Marble, Robert Greif, Keith A. Marill, J. Joelle Donofrio-Odmann, Jon C. Rittenberger, José G. Cabañas, Paul J. Snobelen, Angus Jameson, et al.


  • Open Access

    Implementation of blood culture stewardship during a blood culture bottle shortage: a multicenter assessment

    by Kristen Sevilla, Orest Konyk, Jon C. Rittenberger, Karen S. Williams

    Objective: Assess clinical outcomes, knowledge, and attitudes about shortage mitigation interventions during a nationwide blood culture bottle shortage. We hypothesized that efforts to target ordering of blood cultures would not change patient-oriented outcomes. Design: Retrospective, noninferiority, multicenter study Setting: Tertiary, rural healthcare system Patients: Eligible patients had any culture ordered before and after mitigation strategies. Interventions: Mitigation strategies were rapidly implemented to preserve the availability of blood culture bottles for high-risk patients. Interventions included best practice advisories, algorithms, cascade questions, hard stops, education, and communication. Results: The primary composite outcome (death during hospitalization, death within 14 d after discharge, return to the emergency department (ED) or readmission within 14 d after discharge) occurred in 603 of 3,174 patients (19.0%) in the pregroup and 1,496 of 8,232 patients (18.2%) in the postgroup ( P = 0.321), meeting noninferiority in inverse probability treatment weight (IPTW) analysis. The groups were similar in secondary outcomes and in the subgroup with severe sepsis or septic shock. 69% of 41 survey respondents answered the case questions correctly. Regulatory pressure and patient status were the strongest drivers of blood culture ordering. Clinicians favored in-person communication, algorithms, and cascade over emails, daily huddles, and hard stops/second signatures. Conclusions: Implementation of mitigation strategies during the shortage was not associated with differences in outcomes including mortality, return to the ED, readmission, or length of stay. Preliminary evidence suggests that outcomes may not be affected by the absence of blood cultures in high-risk sepsis patients. If proven in future studies, sepsis recommendations could be rewritten to accommodate pretest probability for bacteremia.


  • Open Access

    American Heart Association Automated External Defibrillator Symposium: Summary and Recommendations

    by José G. Cabañas, Comilla Sasson, Benjamin S. Abella, Tom P. Aufderheide, Lance B. Becker, Katie N. Dainty, Carolina Malta‐Hansen, Rudolph W. Koster, Michael C. Kurz, Keith A. Marill, et al.

    The American Heart Association (AHA) introduced public access defibrillation more than 30 years ago. Since then, we have seen the growth of public access defibrillation programs across many settings within communities. However, despite high expectations that the availability of automated external defibrillators (AEDs) and more integrated public access defibrillation programs would dramatically increase cardiac arrest survival, AEDs are used in the United States in only 4% of out‐of‐hospital cardiac arrests and survival rates have remained disappointingly low. In follow‐up to a recent International Liaison Committee on Resuscitation report, an AED Symposium was organized by members of the AHA Emergency Cardiovascular Care Committee to establish a strategic roadmap for AED technology, education and training, and real‐world use of these devices, including integration with public access defibrillation programs to meet the AHA's goal of doubling out‐of‐hospital cardiac arrests survival by 2030. The meeting brought together a diverse group of subject matter experts including representatives from the US Food and Drug Administration, the defibrillator industry, clinicians, and scientists. This paper summarizes the proceedings of the AED symposium and suggests a set of strategic recommendations to ultimately improve survival from cardiac arrest.


  • Comparing Hypothermic and Thermal Neutral Conditions to Induce Metabolic Suppression

    by Jon C. Rittenberger, Brian M. Clemency, Brian Monaco, Jacqueline Schwob, Joshua T. Murphey, David Hostler

    Suppressing metabolism in astronauts could decrease CO2 production. It is unknown whether active cooling is required to suppress metabolism in sedated patients. We hypothesized that hypothermia would have an additive effect with dexmedetomidine on suppressing metabolism. This is a randomized crossover trial of healthy subjects receiving sedation with dexmedetomidine and exposure to a cold (20°C) or thermal neutral (31°C) environment for 3 hours. We measured heart rate, blood pressure, core temperature, resting oxygen consumption (VO2), resting carbon dioxide production (VCO2), and resting energy expenditure (REE) at baseline and each hour of exposure to either environment. We also evaluated components of the Defense Automated Neurobehavioral Assessment (DANA) Brief to evaluate the effect of metabolic suppression on cognition. Six subjects completed the study. Heart rate and core temperature were lower during the cold (56 bpm) condition than the thermal neutral condition (67 bpm). VO2, VCO2, and REE decreased between baseline and the 3-hour measurement in the cold condition (Δ = 0.9 mL/min, 56.94 mL/min, 487.9 Kcal/D, respectively). DANA simple response time increased between baseline and start of recovery in both conditions (20°C 136.9 cognitive efficiency [CE] and 31°C 87.83 CE). DANA procedural reaction time increased between baseline and start of recovery in the cold condition (220.6 CE) but not in the thermal neutral condition. DANA Go/No-Go time increased between baseline and start of recovery in both conditions (20°C 222.1 CE and 31°C 122.3 CE). Sedation and cold environments are required for metabolic suppression. Subjects experienced decrements in cognitive performance in both conditions. A significant recovery period may be required after metabolic suppression before completing mission critical tasks.


  • Metabolic Manipulation and Therapeutic Hypothermia

    by Katharyn L. Flickinger, Alexandra Weissman, Jonathan Elmer, Patrick J. Coppler, Francis X. Guyette, Melissa J. Repine, Cameron Dezfulian, David Hopkins, Adam Frisch, Ankur A. Doshi, et al.

    Hypothermia has multiple physiological effects, including decreasing metabolic rate and oxygen consumption (VO 2 ). There are few human data about the magnitude of change in VO 2 with decreases in core temperature. We aimed to quantify to magnitude of reduction in resting VO 2 as we reduced core temperature in lightly sedated healthy individuals. After informed consent and physical screening, we cooled participants by rapidly infusing 20 mL/kg of cold (4°C) saline intravenously and placing surface cooling pads on the torso. We attempted to suppress shivering using a 1 mcg/kg intravenous bolus of dexmedetomidine followed by titrated infusion at 1.0 to 1.5 μg/(kg·h). We measured resting metabolic rate VO 2 through indirect calorimetry at baseline (37°C) and at 36°C, 35°C, 34°C, and 33°C. Nine participants had mean age 30 (standard deviation 10) years and 7 (78%) were male. Baseline VO 2 was 3.36 mL/(kg·min) (interquartile range 2.98–3.76) mL/(kg·min). VO 2 was associated with core temperature and declined with each degree decrease in core temperature, unless shivering occurred. Over the entire range from 37°C to 33°C, median VO 2 declined 0.7 mL/(kg·min) (20.8%) in the absence of shivering. The largest average decrease in VO 2 per degree Celsius was by 0.46 mL/(kg·min) (13.7%) and occurred between 37°C and 36°C in the absence of shivering. After a participant developed shivering, core body temperature did not decrease further, and VO 2 increased. In lightly sedated humans, metabolic rate decreases around 5.2% for each 1°C decrease in core temperature from 37°C to 33°C. Because the largest decrease in metabolic rate occurs between 37°C and 36°C, subclinical shivering or other homeostatic reflexes may be present at lower temperatures.


  • Open Access

    A multicenter, randomized, doubleblind, placebo-controlled trial of amantadine to stimulate awakening in comatose patients resuscitated from cardiac arrest

    by Patrick J. Coppler, David J. Gagnon, Katharyn L. Flickinger, Jonathan Elmer, Clifton W. Callaway, Francis X. Guyette, Ankur Doshi, Alexis Steinberg, Cameron Dezfulian, Ari L. Moskowitz, et al.

    Objective We hypothesized that the administration of amantadine would increase awakening of comatose patients resuscitated from cardiac arrest. Methods We performed a prospective, randomized, controlled pilot trial, randomizing subjects to amantadine 100 mg twice daily or placebo for up to 7 days. The study drug was administered between 72 and 120 hours after resuscitation and patients with absent N20 cortical responses, early cerebral edema, or ongoing malignant electroencephalography patterns were excluded. Our primary outcome was awakening, defined as following two-step commands, within 28 days of cardiac arrest. Secondary outcomes included length of stay, awakening, time to awakening, and neurologic outcome measured by Cerebral Performance Category at hospital discharge. We compared the proportion of subjects awakening and hospital survival using Fisher exact tests and time to awakening and hospital length of stay using Wilcoxon rank sum tests. Results After 2 years, we stopped the study due to slow enrollment and lapse of funding. We enrolled 14 subjects (12% of goal enrollment), seven in the amantadine group and seven in the placebo group. The proportion of patients who awakened within 28 days after cardiac arrest did not differ between amantadine (n=2, 28.6%) and placebo groups (n=3, 42.9%; P>0.99). There were no differences in secondary outcomes. Study medication was stopped in three subjects (21.4%). Adverse events included a recurrence of seizures (n=2; 14.3%), both of which occurred in the placebo group.


  • Open Access

    Effect of stomach inflation during cardiopulmonary resuscitation on return of spontaneous circulation in out-of-hospital cardiac arrest patients: A retrospective observational study

    by Hiromichi Naito, Hiroaki Hanafusa, Takashi Hongo, Tetsuya Yumoto, Takashi Yorifuji, Alexandra Weissman, Jon C. Rittenberger, Francis X. Guyette, Mamoru Fujishima, Hiroki Maeyama, et al.


  • External validation of Pittsburgh Cardiac Arrest Category illness severity score

    by Michelle M.J. Nassal, Dylan Nichols, Stephanie Demasi, Jon C. Rittenberger, Ashish R. Panchal, Michael C. Kurz


  • Glycopyrrolate does not ameliorate hypothermia associated bradycardia in healthy individuals: A randomized crossover trial

    by Jon C. Rittenberger, Alexandra Weissman, Katharyn L. Flickinger, Francis X. Guyette, David Hopkins, Melissa J. Repine, Cameron Dezfulian, Ankur A. Doshi, Jonathan Elmer, Kelly N. Sawyer, et al.